Bibliometric analysis of residual cardiovascular risk: trends and frontiers

被引:3
作者
Wang, Lin [1 ]
Wang, Sutong [1 ]
Song, Chaoyuan [1 ,4 ]
Yu, Yiding [1 ]
Jiang, Yuehua [3 ]
Wang, Yongcheng [2 ]
Li, Xiao [2 ]
机构
[1] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Dept Cardiovasc, Affiliated Hosp, Jinan, Peoples R China
[3] Shandong Univ Tradit Chinese Med, Cent Lab, Affiliated Hosp, Jinan 250011, Peoples R China
[4] Zibo Cent Hosp, Dept Neurol, Zibo, Peoples R China
基金
中国国家自然科学基金;
关键词
Residual cardiovascular risk; Bibliometric analysis; CiteSpace; VOSviewer; C-REACTIVE PROTEIN; REMNANT CHOLESTEROL; LDL-CHOLESTEROL; STATIN THERAPY; FENOFIBRATE THERAPY; HDL CHOLESTEROL; VASCULAR RISK; HEART-DISEASE; PREVENTION; EVENTS;
D O I
10.1186/s41043-023-00478-z
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
BackgroundThe presence of residual cardiovascular risk is an important cause of cardiovascular events. Despite the significant advances in our understanding of residual cardiovascular risk, a comprehensive analysis through bibliometrics has not been performed to date. Our objective is to conduct bibliometric studies to analyze and visualize the current research hotspots and trends related to residual cardiovascular risk. This will aid in understanding the future directions of both basic and clinical research in this area.MethodsThe literature was obtained from the Web of Science Core Collection database. The literature search date was September 28, 2022. Bibliometric indicators were analyzed using CiteSpace, VOSviewer, Bibliometrix (an R package), and Microsoft Excel.ResultA total of 1167 papers were included, and the number of publications is increasing rapidly in recent years. The United States and Harvard Medical School are the leading country and institution, respectively, in the study of residual cardiovascular risk. Ridker PM and Boden WE are outstanding investigators in this field. According to our research results, the New England Journal of Medicine is the most influential journal in the field of residual cardiovascular risk, whereas Atherosclerosis boasts the highest number of publications on this topic. Analysis of keywords and landmark literature identified current research hotspots including complications of residual cardiovascular risk, risk factors, and pharmacological prevention strategies.ConclusionIn recent times, global attention toward residual cardiovascular risk has significantly increased. Current research is focused on comprehensive lipid-lowering, residual inflammation risk, and dual-pathway inhibition strategies. Future efforts should emphasize strengthening international communication and cooperation to promote the comprehensive evaluation and management of residual cardiovascular risk.
引用
收藏
页数:23
相关论文
共 125 条
  • [1] PCSK9-targeted therapies: present and future approaches
    Al Rifai, Mahmoud
    Ballantyne, Christie M.
    [J]. NATURE REVIEWS CARDIOLOGY, 2021, 18 (12) : 805 - 806
  • [2] Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS111, DOI [10.2337/dc20-S010, 10.2337/dc20-s010]
  • [3] [Anonymous], 1998, N Engl J Med, V339
  • [4] bibliometrix: An R-tool for comprehensive science mapping analysis
    Aria, Massimo
    Cuccurullo, Corrado
    [J]. JOURNAL OF INFORMETRICS, 2017, 11 (04) : 959 - 975
  • [5] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [6] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [7] Effects of torcetrapib in patients at high risk for coronary events
    Barter, Philip J.
    Caulfield, Mark
    Eriksson, Mats
    Grundy, Scott M.
    Kastelein, John J. P.
    Komajda, Michel
    Lopez-Sendon, Jose
    Mosca, Lori
    Tardif, Jean-Claude
    Waters, David D.
    Shear, Charles L.
    Revkin, James H.
    Buhr, Kevin A.
    Fisher, Marian R.
    Tall, Alan R.
    Brewer, Bryan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2109 - 2122
  • [8] Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
    Basiak, Marcin
    Kosowski, Michal
    Hachula, Marcin
    Okopien, Boguslaw
    [J]. PHARMACEUTICALS, 2022, 15 (07)
  • [9] A scientometric analysis on entrepreneurial intention literature: Delving deeper into local citation
    Batista-Canino, Rosa M.
    Santana-Hernandez, Lidia
    Medina-Brito, Pino
    [J]. HELIYON, 2023, 9 (02)
  • [10] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    Bhatt, Deepak L.
    Steg, P. Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Ketchum, Steven B.
    Doyle, Ralph T., Jr.
    Juliano, Rebecca A.
    Jiao, Lixia
    Granowitz, Craig
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) : 11 - 22